Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBLVN.L Regulatory News (BLVN)

  • There is currently no data for BLVN

Director/PDMR Shareholding

20 Oct 2011 16:47

RNS Number : 5742Q
BowLeven Plc
20 October 2011
 

20 October 2011

 

Bowleven plc ("Bowleven" or the "Company")

 

Directors' interests

 

The Company announces that on 19 October 2011, pursuant to a conditional placing of 77,500,000 new ordinary shares in the capital of the Company at a placing price of 103 pence each, the following dealings (direct or indirect) by directors of Bowleven took place (in accordance with a derogation granted to the Company in respect of AIM rule 21) pursuant to the conditional placing:-

 

Ronnie Hanna, Non-Executive Chairman of the Company, has agreed to subscribe for 20,000 ordinary shares in the Company at a price of 103 pence per share. Subject to the allotment of the placing shares on 8 November 2011, Ronnie Hanna's total beneficial shareholding in the Company will be 330,125 shares which at that time will represent approximately 0.11% of the then enlarged issued share capital of the Company.

 

Kevin Hart, Chief Executive Officer of the Company, has agreed to subscribe for 200,000 ordinary shares in the Company at a price of 103 pence per share. Subject to the allotment of the placing shares on 8 November 2011, Kevin Hart's total beneficial shareholding in the Company will be 2,190,000 shares which at that time will represent approximately 0.75% of the then enlarged issued share capital of the Company.

 

John Brown, Finance Director of the Company, has agreed to subscribe for 25,000 ordinary shares in the Company at a price of 103 pence per share. Subject to the allotment of the placing shares on 8 November 2011, John Brown's total beneficial shareholding in the Company will be 122,675 shares which at that time will represent approximately 0.04% of the then enlarged issued share capital of the Company.

 

Ed Willett, Exploration Director of the Company has agreed to subscribe for 25,000 ordinary shares in the Company at a price of 103 pence per share. Subject to the allotment of the placing shares on 8 November 2011, Ed Willett's total beneficial shareholding in the Company will be 217,235 shares which at that time will represent approximately 0.07% of the then enlarged issued share capital of the Company.

 

Peter Wilson, Director and General Counsel of the Company, has agreed to subscribe for 25,000 ordinary shares in the Company at a price of 103 pence per share. Subject to the allotment of the placing shares on 8 November 2011, Peter Wilson's total beneficial shareholding in the Company will be 277,119 shares which at that time will represent approximately 0.09% of the then enlarged issued share capital of the Company.

 

Tim Sullivan, Non-Executive Director of the Company, has agreed to subscribe for 50,000 ordinary shares in the Company at a price of 103 pence per share. Subject to the allotment of the placing shares on 8 November 2011, Tim Sullivan's total beneficial shareholding in the Company will be 146,745 shares which at that time will represent approximately 0.05% of the then enlarged issued share capital of the Company.

 

The allotment of the new ordinary shares pursuant to the conditional placing is subject to, amongst other things, the required shareholder approval to be sought at the Company's General Meeting being held on Monday 7 November 2011.

 

ENQUIRIES

For further information please contact:

 

Bowleven plc

Kevin Hart, Chief Executive

00 44 131 524 5678

Kerry Crawford, Head of Investor Relations

BofA Merrill Lynch

00 44 207 628 1000

Andrew Osborne

Tony White

Brunswick Group LLP

Patrick Handley

00 44 207 404 5959

Natalia Erikssen

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSPGGQCUUPGGAU
Date   Source Headline
27th Mar 20094:35 pmRNSPrice Monitoring Extension
27th Mar 20094:28 pmRNSStatement re Possible Offer
27th Mar 20092:29 pmRNSRule 8.3- (Bowleven plc)
27th Mar 200911:23 amRNSEPT Disclosure
26th Mar 200911:11 amRNSEPT Disclosure
26th Mar 20099:20 amBUSEPT Disclosure
26th Mar 20098:49 amRNSRule 8.3- Bowleven PLC
25th Mar 200911:11 amRNSEPT Disclosure
25th Mar 200910:40 amRNSHolding(s) in Company
25th Mar 20099:11 amBUSEPT Disclosure
25th Mar 20098:34 amRNSRule 8.3- Bowleven PLC
24th Mar 20092:57 pmRNSRule 8.3- (Bowleven Plc)
24th Mar 200911:17 amRNSEPT Disclosure
24th Mar 200911:06 amBUSEPT Disclosure
24th Mar 200911:03 amBUSEPT Disclosure
24th Mar 200910:54 amRNSHolding(s) in Company
24th Mar 20099:19 amRNSHolding(s) in Company
23rd Mar 20092:45 pmRNSRule 8.3- Bowleven Plc
23rd Mar 200911:35 amRNSEPT Disclosure
23rd Mar 20099:39 amBUSEPT Disclosure
23rd Mar 20097:00 amRNSInterim Results
20th Mar 20093:54 pmRNSHolding(s) in Company
20th Mar 20093:33 pmRNSHolding(s) in Company
20th Mar 20092:56 pmRNSRule 8.3- Bowleven PLC
20th Mar 200910:14 amRNSEPT Disclosure
20th Mar 20099:19 amBUSEPT Disclosure
20th Mar 20099:17 amBUSEPT Disclosure
19th Mar 20093:53 pmBUSEPT Disclosure - Amendment
19th Mar 200910:45 amRNSRule 8.3- Bowleven Plc
19th Mar 200910:24 amBUSEPT Disclosure
19th Mar 200910:06 amRNSEPT Disclosure
19th Mar 20098:45 amRNSRule 2.10 Announcement
18th Mar 20097:37 amRNSStatement re Possible Offer
10th Mar 200911:55 amRNSHolding(s) in Company
22nd Jan 200912:58 pmRNSDirector/PDMR Shareholding
19th Jan 200912:30 pmRNSHolding(s) in Company
19th Jan 20099:09 amRNSDirector/PDMR Shareholding
16th Jan 200911:58 amRNSHolding(s) in Company
16th Jan 20097:00 amRNSDirector/PDMR Shareholding
22nd Dec 20082:47 pmRNSPSC Signing
17th Dec 20084:20 pmRNSHolding(s) in Company
12th Dec 20088:59 amRNSDirector/PDMR Shareholding
11th Dec 20084:40 pmRNSAGM and EGM Results announcement
11th Dec 20084:04 pmRNSAGM Statement
9th Dec 20082:57 pmRNSHolding(s) in Company
9th Dec 200811:04 amRNSDirector/PDMR Shareholding
2nd Dec 20083:31 pmRNSHolding(s) in Company
1st Dec 20083:20 pmRNSHolding(s) in Company
1st Dec 200810:00 amRNSHolding(s) in Company
17th Nov 20081:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.